<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1238" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1238/" /><meta name="ncbi_pagename" content="Krabbe Disease - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Krabbe Disease - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Krabbe Disease" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2018/10/11" /><meta name="citation_author" content="Joseph J Orsini" /><meta name="citation_author" content="Maria L Escolar" /><meta name="citation_author" content="Melissa P Wasserstein" /><meta name="citation_author" content="Michele Caggana" /><meta name="citation_pmid" content="20301416" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1238/" /><meta name="citation_keywords" content="Galactocerebrosidase Deficiency" /><meta name="citation_keywords" content="GALC Deficiency" /><meta name="citation_keywords" content="Globoid Cell Leukodystrophy" /><meta name="citation_keywords" content="GALC Deficiency" /><meta name="citation_keywords" content="Galactosylceramidase Deficiency" /><meta name="citation_keywords" content="Globoid Cell Leukodystrophy" /><meta name="citation_keywords" content="Galactosylcerebrosidase Deficiency" /><meta name="citation_keywords" content="ß-Galactocerebrosidase Deficiency" /><meta name="citation_keywords" content="Galactocerebrosidase" /><meta name="citation_keywords" content="GALC" /><meta name="citation_keywords" content="Krabbe Disease" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Krabbe Disease" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Joseph J Orsini" /><meta name="DC.Contributor" content="Maria L Escolar" /><meta name="DC.Contributor" content="Melissa P Wasserstein" /><meta name="DC.Contributor" content="Michele Caggana" /><meta name="DC.Date" content="2018/10/11" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1238/" /><meta name="description" content="Krabbe disease comprises a spectrum ranging from infantile-onset disease (i.e., onset of extreme irritability, spasticity, and developmental delay before age 12 months) to later-onset disease (i.e., onset of manifestations after age 12 months and as late as the seventh decade). Although historically 85%-90% of symptomatic individuals with Krabbe disease diagnosed by enzyme activity alone have infantile-onset Krabbe disease and 10%-15% have later-onset Krabbe disease, the experience with newborn screening (NBS) suggests that the proportion of individuals with possible later-onset Krabbe disease is higher than previously thought. Infantile-onset Krabbe disease is characterized by normal development in the first few months followed by rapid severe neurologic deterioration; the average age of death is 24 months (range 8 months to 9 years). Later-onset Krabbe disease is much more variable in its presentation and disease course." /><meta name="og:title" content="Krabbe Disease" /><meta name="og:type" content="book" /><meta name="og:description" content="Krabbe disease comprises a spectrum ranging from infantile-onset disease (i.e., onset of extreme irritability, spasticity, and developmental delay before age 12 months) to later-onset disease (i.e., onset of manifestations after age 12 months and as late as the seventh decade). Although historically 85%-90% of symptomatic individuals with Krabbe disease diagnosed by enzyme activity alone have infantile-onset Krabbe disease and 10%-15% have later-onset Krabbe disease, the experience with newborn screening (NBS) suggests that the proportion of individuals with possible later-onset Krabbe disease is higher than previously thought. Infantile-onset Krabbe disease is characterized by normal development in the first few months followed by rapid severe neurologic deterioration; the average age of death is 24 months (range 8 months to 9 years). Later-onset Krabbe disease is much more variable in its presentation and disease course." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1238/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/krabbe/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1238/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE88599FE041D54100000000054B01FB.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1238_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1238_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/mdel17q21_31/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/l1cam/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1238_"><span class="title" itemprop="name">Krabbe Disease</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: Galactocerebrosidase Deficiency, GALC Deficiency, Globoid Cell Leukodystrophy</div><p class="contrib-group"><span itemprop="author">Joseph J Orsini</span>, PhD, <span itemprop="author">Maria L Escolar</span>, MD, MS, <span itemprop="author">Melissa P Wasserstein</span>, MD, and <span itemprop="author">Michele Caggana</span>, ScD.</p><a data-jig="ncbitoggler" href="#__NBK1238_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1238_ai__"><div class="contrib half_rhythm"><span itemprop="author">Joseph J Orsini</span>, PhD<div class="affiliation small">Wadsworth Center<br />New York State Department of Health<br />Albany, New York<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.yn.htlaeh@inisro.hpesoj" class="oemail">vog.yn.htlaeh@inisro.hpesoj</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Maria L Escolar</span>, MD, MS<div class="affiliation small">Children's Hospital of Pittsburgh &#x02013; UPMC<br />University of Pittsburgh<br />Pittsburgh, Pennsylvania<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.phc@ralocse.airam" class="oemail">ude.phc@ralocse.airam</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Melissa P Wasserstein</span>, MD<div class="affiliation small">Children's Hospital at Montefiore;<br />Albert Einstein College of Medicine<br />Bronx, New York<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.eroifetnom@sressawm" class="oemail">gro.eroifetnom@sressawm</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Michele Caggana</span>, ScD<div class="affiliation small">Wadsworth Center<br />New York State Department of Health<br />Albany, New York<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.yn.htlaeh@anaggac.elehcim" class="oemail">vog.yn.htlaeh@anaggac.elehcim</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">June 19, 2000</span>; Last Update: <span itemprop="dateModified">October 11, 2018</span>.</p><p><em>Estimated reading time: 28 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="krabbe.Summary" itemprop="description"><h2 id="_krabbe_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Krabbe disease comprises a spectrum ranging from infantile-onset disease (i.e., onset of extreme irritability, spasticity, and developmental delay before age 12 months) to later-onset disease (i.e., onset of manifestations after age 12 months and as late as the seventh decade). Although historically 85%-90% of symptomatic individuals with Krabbe disease diagnosed by enzyme activity alone have infantile-onset Krabbe disease and 10%-15% have later-onset Krabbe disease, the experience with <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> (NBS) suggests that the proportion of individuals with possible later-onset Krabbe disease is higher than previously thought. Infantile-onset Krabbe disease is characterized by normal development in the first few months followed by rapid severe neurologic deterioration; the average age of death is 24 months (range 8 months to 9 years). Later-onset Krabbe disease is much more variable in its presentation and disease course.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The two diagnostic scenarios are the following:</p><ul><li class="half_rhythm"><div>Scenario 1. The diagnosis of Krabbe disease, suspected in a symptomatic <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> based on clinical findings (by age) and other supportive laboratory, neuroimaging, and electrophysiologic findings, is established by detection of deficient GALC enzyme activity in leukocytes. Abnormal results require follow-up <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>GALC;</i> elevated psychosine levels can also help establish the diagnosis.</div></li><li class="half_rhythm"><div>Scenario 2. In an asymptomatic newborn with low GALC enzyme activity on dried blood spot specimens on NBS urgent time-critical measurement of blood psychosine levels and <i>GALC</i> <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> is necessary to identify &#x02013; before age 14 days &#x02013; those newborns with evidence of infantile-onset Krabbe disease who are candidates for early treatment with hematopoietic stem cell transplantation (HSCT).</div></li></ul></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Treatment of a child who is symptomatic before age six months is supportive and focused on increasing the quality of life and avoiding complications. For older individuals, treatment with HSCT is individualized based on disease burden and manifestations.</p><p><i>Prevention of primary manifestations:</i> Consensus guidelines recommend that asymptomatic newborns identified by either prenatal/neonatal evaluation because of a positive family history of Krabbe disease or an abnormal NBS result undergo additional testing to identify those with infantile-onset Krabbe disease. Those with laboratory findings consistent with infantile-onset Krabbe disease are candidates for HSCT before age 30 days.</p><p><i>Surveillance:</i> Monitor symptomatic individuals with Krabbe disease for development of: hydrocephalus, swallowing difficulties and chronic microaspiration, scoliosis, hip subluxation, and osteopenia, decreased vision, and corneal ulcerations.</p><p><i>Agents/circumstances to avoid:</i> Atypical antipsychotics and multiple medications for seizures can cause over-sedation (affecting cognition, respiratory drive, and rate of neurologic decline). Routine childhood vaccinations can accelerate disease progression.</p><p><i>Evaluation of relatives at risk:</i> Couples who have had one child with molecularly confirmed infantile-onset Krabbe disease may choose prenatal <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> in subsequent pregnancies so that newborns with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>GALC</i> pathogenic variants can be promptly tested and &#x02013; if appropriate -- referred for HSCT.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>Krabbe disease is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Once the <i>GALC</i> pathogenic variants have been identified in an affected family member, <a class="def" href="/books/n/gene/glossary/def-item/carrier-testing/">carrier testing</a> for at-risk relatives, prenatal testing for a pregnancy at increased risk, and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p></div></div><div id="krabbe.Diagnosis"><h2 id="_krabbe_Diagnosis_">Diagnosis</h2><p>Krabbe disease (also known as galactocerebrosidase [GALC] deficiency) has two major phenotypes that constitute a continuum:</p><ul><li class="half_rhythm"><div>Infantile-onset Krabbe disease (onset &#x0003c;12 months), characterized by progressive neurologic deterioration in infancy and death before age two years (85%-90% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals)</div></li><li class="half_rhythm"><div>Later-onset Krabbe disease (onset &#x0003e;12 months), with slower disease progression (10%-15%)</div></li></ul><div id="krabbe.Suggestive_Findings"><h3>Suggestive Findings</h3><p>The two different scenarios in which Krabbe disease could be suspected in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>:</p><ul><li class="half_rhythm"><div><b>Scenario 1.</b> A symptomatic individual</div></li><li class="half_rhythm"><div><b>Scenario 2.</b> An asymptomatic newborn with a positive result on NBS</div></li></ul><div id="krabbe.Scenario_1"><h4>Scenario 1</h4><p>Krabbe disease <b>should be suspected</b> in a <b>symptomatic <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b> based on <b>clinical findings</b> (by age) and other supportive <b>laboratory</b>, <b>neuroimaging</b>, and <b>electrophysiologic findings</b>.</p><p><b>Clinical findings</b></p><p><b>Age &#x0003c;12 months</b> (infantile-onset Krabbe disease)</p><ul><li class="half_rhythm"><div>Excessive crying to extreme irritability</div></li><li class="half_rhythm"><div>Feeding difficulties, gastroesophageal reflux disease</div></li><li class="half_rhythm"><div>Spasticity of lower extremities and fisting, with axial hypotonia</div></li><li class="half_rhythm"><div>Loss of acquired milestones (smiling, cooing, and head control)</div></li><li class="half_rhythm"><div>Staring episodes</div></li><li class="half_rhythm"><div>Peripheral neuropathy</div></li></ul><p><b>Age &#x0003e;12 months</b> (later-onset Krabbe disease)</p><ul><li class="half_rhythm"><div>Slow development of motor milestones or loss of milestones (e.g., sitting without support, walking), slurred speech</div></li><li class="half_rhythm"><div>Spasticity of extremities with truncal hypotonia</div></li><li class="half_rhythm"><div>Vision loss, esotropia</div></li><li class="half_rhythm"><div>Seizures</div></li><li class="half_rhythm"><div>Peripheral neuropathy</div></li></ul><p><b>Other supportive findings</b></p><ul><li class="half_rhythm"><div class="half_rhythm">Increased cerebrospinal fluid (CSF) protein concentration. Ranges vary by age and laboratory, normal infant range reported at 48-72 mg/dL [<a class="bk_pop" href="#krabbe.REF.shah.2011.22">Shah et al 2011</a>]. Adult range: 18-58 mg/dL.</div><div class="half_rhythm">Note: CSF protein concentration is already increased in Stage I infantile-onset Krabbe disease (see <a href="#krabbe.Clinical_Description">Clinical Description</a>).</div></li><li class="half_rhythm"><div class="half_rhythm">MRI (infantile-onset Krabbe disease) observed within the first few months of age</div></li><li class="half_rhythm"><div class="half_rhythm">Abnormal brain MRI, consistent with demyelination. T<sub>2</sub>-weighted images show involvement of periventricular white matter, deep gray matter, and centrum semiovale as well as enhancement of cranial nerves. <a href="https://radiopaedia.org/articles/subcortical-u-fibres-3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Subcortical U-fiber</a>s may be spared until late in the disease course [<a class="bk_pop" href="#krabbe.REF.gupta.2014.792">Gupta et al 2014</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">Abnormal spine MRI (enhancement of spinal nerve roots)</div></li><li class="half_rhythm"><div class="half_rhythm">Abnormal electrophysiologic studies (nerve conduction velocity, brain stem auditory evoked response, visual evoked potentials)</div></li></ul></div><div id="krabbe.Scenario_2"><h4>Scenario 2</h4><p>Krabbe disease <b>should be suspected</b> in <b>an asymptomatic newborn</b> with a <b>positive result</b> on <b>NBS</b>.</p><p>Currently, seven states (Illinois, Kentucky, Missouri, New York, Ohio, Pennsylvania, and Tennessee) perform NBS for GALC deficiency using dried blood spots. While the approaches to testing and cut-off values indicating a positive newborn screen vary by state, all results suggesting GALC deficiency require immediate follow-up studies (see Establishing the Diagnosis, <a href="#krabbe.Scenario_2_1">Scenario 2</a>).</p></div></div><div id="krabbe.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><div id="krabbe.Scenario_1_1"><h4>Scenario 1</h4><p><b>The testing required to establish the diagnosis Krabbe disease in a symptomatic <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> In individuals with some or all of the suggestive findings of infantile-onset Krabbe disease or later-onset Krabbe disease, the diagnosis is established by detection of deficient GALC enzyme activity in leukocytes. Abnormal results require follow-up <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>GALC.</i> For children with infantile-onset Krabbe disease, elevated psychosine levels in dried blood spot specimens confirm the diagnosis; however, in individuals who have later-onset Krabbe disease or have progressed to the later stages of the infantile form of disease, it is not yet known if psychosine concentrations are consistently elevated.</p><p><b>Galactocerebrosidase</b>
<b>(GALC) enzyme activity</b> is measured in leukocytes isolated from whole heparinized blood or cultured skin fibroblasts. The substrate used (i.e., radiometric substrate, fluorescent substrate, or mass spectrometry substrate) depends on the laboratory.</p><ul><li class="half_rhythm"><div>Very low GALC enzyme activity (0%-5% of normal activityl) is observed in all individuals with Krabbe disease who are symptomatic. Note: Low GALC activity can result from pseudodeficiency alleles (benign <i>GALC</i> variants that reduce enzyme activity in vitro but do not cause disease), <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status for a <i>GALC</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, or saposin A deficiency (see <a href="#krabbe.Molecular_Genetics">Molecular Genetics</a>).</div></li><li class="half_rhythm"><div>If GALC enzyme activity in leukocytes is completely normal, no additional biochemical testing is required to exclude Krabbe disease. However, if psychosine was elevated in such cases, a diagnosis of saposin A deficiency should be considered.</div></li></ul><p><b>Psychosine concentration</b></p><ul><li class="half_rhythm"><div><b>Infantile-onset Krabbe disease.</b> Very elevated concentrations of psychosine (usually &#x0003e;10 nmol/L) are strongly supportive of early symptomatic Krabbe disease [<a class="bk_pop" href="#krabbe.REF.turgeon.2015.923">Turgeon et al 2015</a>, <a class="bk_pop" href="#krabbe.REF.escolar.2017.271">Escolar et al 2017</a>, <a class="bk_pop" href="#krabbe.REF.minter_baerg.2018.847">Minter Baerg et al 2018</a>]. Note that psychosine concentrations may drop significantly in the later stages of infantile-onset Krabbe disease and that psychosine may also be elevated in individuals with saposin A deficiency.</div></li><li class="half_rhythm"><div><b>Later-onset Krabbe disease.</b> Psychosine concentrations may not be markedly elevated and may depend on how long the patient has been symptomatic [<a class="bk_pop" href="#krabbe.REF.escolar.2017.271">Escolar et al 2017</a>].</div></li></ul><p><b>Molecular testing involves single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>GALC</i> and targeted analysis for the common <i>GALC</i> 30-kilobase <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> (30kb del) is performed [<a class="bk_pop" href="#krabbe.REF.luzi.1995.2335">Luzi et al 1995</a>, <a class="bk_pop" href="#krabbe.REF.rafi.1995.1285">Rafi et al 1995</a>]. Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> should also be performed, at least when the suspicion of Krabbe disease is high and only one <i>GALC</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been detected by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>. See <a class="figpopup" href="/books/NBK1238/table/krabbe.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-figpopup="figkrabbeTmoleculargenetictestingused" rid-ob="figobkrabbeTmoleculargenetictestingused">Table 1</a>.</p><div id="krabbe.T.molecular_genetic_testing_used" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Krabbe Disease (Galactosylcerebrosidase Deficiency)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1238/table/krabbe.T.molecular_genetic_testing_used/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__krabbe.T.molecular_genetic_testing_used_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_krabbe.T.molecular_genetic_testing_used_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_krabbe.T.molecular_genetic_testing_used_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_krabbe.T.molecular_genetic_testing_used_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_krabbe.T.molecular_genetic_testing_used_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>GALC</i></td><td headers="hd_h_krabbe.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_krabbe.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">55%-65%&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_krabbe.T.molecular_genetic_testing_used_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Targeted analysis for 30kb del</td><td headers="hd_h_krabbe.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">35%-45%&#x000a0;<sup>5</sup></td></tr><tr><td headers="hd_h_krabbe.T.molecular_genetic_testing_used_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>6</sup></td><td headers="hd_h_krabbe.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 7</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="krabbe.TF.1.1"><p class="no_margin">See <a href="/books/NBK1238/#krabbe.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="krabbe.TF.1.2"><p class="no_margin">See <a href="#krabbe.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="krabbe.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="krabbe.TF.1.4"><p class="no_margin"><a class="bk_pop" href="#krabbe.REF.wenger.2013">Wenger et al [2013]</a>, <a class="bk_pop" href="#krabbe.REF.orsini.2016.239">Orsini et al [2016]</a></p></div></dd><dt>5. </dt><dd><div id="krabbe.TF.1.5"><p class="no_margin">This large <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> accounts for approximately 35% of the pathogenic variants in individuals with Krabbe disease of Mexican heritage [D.Wenger, personal experience] and 45% of the pathogenic variants in individuals with Krabbe disease of European ancestry [<a class="bk_pop" href="#krabbe.REF.luzi.1995.2335">Luzi et al 1995</a>, <a class="bk_pop" href="#krabbe.REF.rafi.1995.1285">Rafi et al 1995</a>].</p></div></dd><dt>6. </dt><dd><div id="krabbe.TF.1.6"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>7. </dt><dd><div id="krabbe.TF.1.7"><p class="no_margin">Deletions involving single exons and multiple exons, other than the common 30-kb <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>, are rare but have been reported [<a class="bk_pop" href="#krabbe.REF.wenger.2001">Wenger et al 2001</a>, <a class="bk_pop" href="#krabbe.REF.tanner.2012.38">Tanner et al 2012</a>].</p></div></dd></dl></div></div></div></div><div id="krabbe.Scenario_2_1"><h4>Scenario 2</h4><p><b>The testing required to establish the diagnosis Krabbe disease in an asymptomatic infant identified on NBS.</b> Presumptive positive <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> results for Krabbe disease must be followed up urgently with time-critical biochemical and molecular genetic studies to identify those newborns with biochemical and molecular genetic evidence of infantile-onset Krabbe disease before age 14 days who are candidates for early treatment with hematopoietic stem cell transplantation (HSCT) (see Management, <a href="#krabbe.Prevention_of_Primary_Manifestati">Prevention of Primary Manifestations</a>) [<a class="bk_pop" href="#krabbe.REF.wasserstein.2016.1235">Wasserstein et al 2016</a>, <a class="bk_pop" href="#krabbe.REF.kwon.2018.30">Kwon et al 2018</a>].</p><p>Note that regardless of the method used to assay GALC enzyme activity, low GALC activity in dried blood spots and/or leukocytes in asymptomatic newborns is not sufficiently specific to diagnose Krabbe disease, let alone to distinguish between infantile-onset and later-onset Krabbe disease. In addition to certain environmental factors, low GALC activity can result from pseudodeficiency alleles (benign <i>GALC</i> variants that reduce enzyme activity <i>in vitro</i> but do not cause disease), heterozygosity (i.e., <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> state) for one <i>GALC</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, and <i>GALC</i> variants observed in later-onset Krabbe disease.</p><ul><li class="half_rhythm"><div><b>The first step in testing an asymptomatic newborn with low GALC enzyme activity identified on NBS.</b> Measurement of concentration of psychosine in the blood (either a punch from the original NBS dried blood spot specimen or a subsequent sample). Very elevated concentration of psychosine (&#x0003e;10 nmol/L) appears to be specific for severe infantile Krabbe disease [<a class="bk_pop" href="#krabbe.REF.turgeon.2015.923">Turgeon et al 2015</a>, <a class="bk_pop" href="#krabbe.REF.escolar.2017.271">Escolar et al 2017</a>, <a class="bk_pop" href="#krabbe.REF.minter_baerg.2018.847">Minter Baerg et al 2018</a>] and warrants next-step testing [<a class="bk_pop" href="#krabbe.REF.kwon.2018.30">Kwon et al 2018</a>].</div></li><li class="half_rhythm"><div><b>Testing for an asymptomatic newborn with low GALC enzyme activity and very elevated concentration of psychosine identified on NBS</b></div><ul><li class="half_rhythm"><div>Sequence analysis of <i>GALC</i> to detect small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants</div></li><li class="half_rhythm"><div>Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> to detect intragenic deletions or duplications including the common 30kb deletion (<a class="figpopup" href="/books/NBK1238/table/krabbe.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-figpopup="figkrabbeTmoleculargenetictestingused" rid-ob="figobkrabbeTmoleculargenetictestingused">Table 1</a>).</div></li></ul></li></ul><p><b>Note:</b> (1) The common 30-kb <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> may be tested for by <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>-specific or breakpoint <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> as part of the first-tier sequencing assay [<a class="bk_pop" href="#krabbe.REF.luzi.1995.2335">Luzi et al 1995</a>, <a class="bk_pop" href="#krabbe.REF.rafi.1995.1285">Rafi et al 1995</a>]. (2) The necessary turn-around time for sequencing and <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> in this scenario is shorter than routinely offered for diagnostic purposes; therefore, specific arrangements need to be made to ensure expedited testing.</p><p>Identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>GALC</i> pathogenic variants known to be associated with infantile-onset Krabbe disease or classified as pathogenic or likely pathogenic further confirms the diagnosis of infantile-onset Krabbe disease [<a class="bk_pop" href="#krabbe.REF.orsini.2016.239">Orsini et al 2016</a>].</p><p>Of note, the vast majority of infants identified through the New York State NBS program who have low GALC enzyme activity and two presumptive pathogenic <i>GALC</i> variants do not have signs or symptoms of infantile-onset disease [<a class="bk_pop" href="#krabbe.REF.wasserstein.2016.1235">Wasserstein et al 2016</a>] and thus are considered to be at risk for later-onset Krabbe disease. A revised definition of risk for infantile-onset Krabbe disease based on results of psychosine concentration and <i>GALC</i> <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> that is under review is expected to significantly decrease the proportion of infants designated as at risk for infantile-onset Krabbe disease identified by NBS [Author, personal communication].</p></div></div></div><div id="krabbe.Clinical_Characteristics"><h2 id="_krabbe_Clinical_Characteristics_">Clinical Characteristics</h2><div id="krabbe.Clinical_Description"><h3>Clinical Description</h3><p>Historically, 85%-90% of symptomatic individuals with Krabbe disease diagnosed by enzyme activity alone had infantile-onset Krabbe disease (i.e., onset of extreme irritability, spasticity, and developmental delay before age 12 months) and 10%-15% had later-onset Krabbe disease (i.e., onset of manifestations after age 12 months and as late as the seventh decade). In contrast, the vast majority of infants identified through the New York State <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> (NBS) program who have low GALC enzyme activity and two presumptive pathogenic <i>GALC</i> variants do not have signs or symptoms of infantile-onset disease [<a class="bk_pop" href="#krabbe.REF.wasserstein.2016.1235">Wasserstein et al 2016</a>]; thus, it is likely that the proportion of individuals with later-onset Krabbe disease is higher than previously thought [Author, personal communication].</p><div id="krabbe.InfantileOnset_Krabbe_Disease"><h4>Infantile-Onset Krabbe Disease</h4><p>Infantile-onset Krabbe disease typically has four stages:</p><ul><li class="half_rhythm"><div><b>Stage I.</b> The infant, apparently normal for the first few months after birth, begins to cry frequently without apparent cause. Many keep their hands tightly fisted. Feeding difficulties and gastroesophageal reflux may result in progressive weight loss leading to emaciation. In some infants, peripheral neuropathy is a presenting feature with no other neurologic features appreciated for several months [<a class="bk_pop" href="#krabbe.REF.kornlubetzki.2003.115">Korn-Lubetzki et al 2003</a>].</div></li><li class="half_rhythm"><div><b>Stage II</b> is characterized by rapid severe neurologic deterioration with decorticate posturing (marked hypertonicity with extended and crossed legs, flexed arms, and trunk hyperextension [opisthotonus]). Tendon reflexes are absent. Staring episodes and minor muscle spasms occur. Optic atrophy and sluggish pupillary reactions to light are common.</div></li><li class="half_rhythm"><div><b>Stage III</b> is characterized by poor control of temperature and heart rate, as well as blindness, deafness, and seizures.</div></li><li class="half_rhythm"><div><b>Stage IV</b> is characterized by very low muscle tone and absence of voluntary movement.</div></li></ul><p>The average age of death in children with infantile-onset Krabbe disease is 24 months; however, some succumb by age eight months from infections and respiratory failure, while others live up to age nine years.</p><p>Symptoms and signs are confined to the nervous system. No visceromegaly is present. Head size may be large or small; hydrocephalus with increased intracranial pressure has been observed. Macular cherry-red spots were described in one individual.</p><p>One infant, diagnosed with GALC deficiency <i>in utero</i>, had normal psychomotor development for the first two months of life but lost deep tendon reflexes by age five weeks, had markedly reduced nerve conduction velocities at age seven weeks, and developed neck muscle weakness at age three months [<a class="bk_pop" href="#krabbe.REF.lieberman.1980.446">Lieberman et al 1980</a>]. These findings suggest that detailed examination could reveal clinical manifestations of infantile-onset Krabbe disease earlier than the reported age of onset.</p><p>Some infants with a positive NBS (and subsequently confirmed to have infantile-onset Krabbe disease) had at least one of the following in the first weeks of life: clonus in the lower extremities, difficulty feeding, abnormal nerve conduction velocity, elevated CSF protein, abnormal brain MRI.</p></div><div id="krabbe.LaterOnset_Krabbe_Disease"><h4>Later-Onset Krabbe Disease</h4><p>Children with onset between ages 12 months and three years can be clinically normal until they manifest gait changes, hemiplegia/diplegia, visual impairment, febrile seizures, and/or tremors. Because myelination occurs very rapidly between birth and age two years, symptoms develop more rapidly at this age than after age two years.</p><p>Children with disease onset between ages 24 months and four years can initially manifest loss of milestones and vision (including rapid loss of vision) or gait changes and seizures.</p><p>Although disease progression is variable, children who develop symptoms between ages nine months and four years may have rapid worsening of symptoms shortly after presentation. In most instances death occurs approximately four to six years after onset [M Escolar, personal communication].</p><p>Initial manifestations in children older than age six years may be behavioral difficulties (attention-deficit/hyperactivity disorder and mood disorders) followed by motor difficulty. They often decline rapidly soon after disease onset [<a class="bk_pop" href="#krabbe.REF.fiumara.2011.452">Fiumara et al 2011</a>].</p><p>Some individuals with onset in adolescence and adulthood present with loss of manual dexterity, burning paresthesias in their extremities, and weakness without intellectual deterioration; others become bedridden and continue to deteriorate mentally and physically [<a class="bk_pop" href="#krabbe.REF.kolodny.1991.232">Kolodny et al 1991</a>, <a class="bk_pop" href="#krabbe.REF.satoh.1997.1392">Satoh et al 1997</a>, <a class="bk_pop" href="#krabbe.REF.jardim.1999.1014">Jardim et al 1999</a>, <a class="bk_pop" href="#krabbe.REF.wenger.2003">Wenger 2003</a>]. Presenting manifestations in adult-onset disease can also include unilateral upper-limb weakness and lower-limb hypoesthesia [<a class="bk_pop" href="#krabbe.REF.debs.2013.859">Debs et al 2013</a>]. Disease progression is generally slower in the adult-onset disease than in adolescent-onset disease.</p><p>The adult-onset group includes individuals in whom the diagnosis was first made in adulthood (because the subtle symptoms present earlier in life did not prompt biochemical testing) as well as individuals considered completely normal until manifestations began after age 20 years [<a class="bk_pop" href="#krabbe.REF.kolodny.1991.232">Kolodny et al 1991</a>, <a class="bk_pop" href="#krabbe.REF.satoh.1997.1392">Satoh et al 1997</a>, <a class="bk_pop" href="#krabbe.REF.wenger.2003">Wenger 2003</a>]. An example of the former is a woman reported by <a class="bk_pop" href="#krabbe.REF.kolodny.1991.232">Kolodny et al [1991]</a> (case 15) who had been "shaky" in childhood, walked slowly with a stiff and wide-based gait, and had progressive, generalized neurologic deterioration after age 40 years. She died of pneumonia at age 73 years. An example of the latter is a woman who developed slowly progressive spastic paraparesis at age 38 years. Demyelination identified on MRI was confined to the corticospinal tract [<a class="bk_pop" href="#krabbe.REF.satoh.1997.1392">Satoh et al 1997</a>].</p><p>Peripheral neuropathy is less common in later-onset disease (affecting about half of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals) than in infantile-onset disease (affecting nearly all affected individuals) [<a class="bk_pop" href="#krabbe.REF.husain.2004.617">Husain et al 2004</a>, <a class="bk_pop" href="#krabbe.REF.siddiqi.2006.263">Siddiqi et al 2006</a>, <a class="bk_pop" href="#krabbe.REF.debs.2013.859">Debs et al 2013</a>].</p><p>Survival varies widely among persons with later-onset disease; the median age is eight years after symptom onset [<a class="bk_pop" href="#krabbe.REF.bascou.2018.126">Bascou et al 2018</a>].</p><p><b>Neurophysiologic findings</b> in later-onset Krabbe disease include the following:</p><ul><li class="half_rhythm"><div><b>Electroencephalogram (EEG).</b> While normal in the initial stages, the EEG gradually becomes abnormal. Background activity becomes slow and disorganized, with changes that may be asymmetric.</div></li><li class="half_rhythm"><div><b>Cerebrospinal fluid protein levels</b> can vary widely but are always elevated in the infantile-onset disease.</div></li><li class="half_rhythm"><div><b>Electrophysiologic studies.</b> Although motor nerve conduction velocities are generally low, they are normal in some adults with an enzymatically confirmed diagnosis.</div></li></ul><p><b>MRI.</b> In general, brain MRI detects demyelination in the brain stem and cerebellum more clearly than CT in the early stage of later-onset Krabbe disease; however, some infants younger than age six months have a deceptively normal MRI because of the low contrast between gray and white matter in this period of brain development. Of note, scoring of atrophy of the midbrain assists in evaluating general disease progression [<a class="bk_pop" href="#krabbe.REF.zuccoli.2015.739">Zuccoli et al 2015</a>].</p><p><b>Diffusion tensor imaging (DTI) of the brain.</b> DTI is the preferred imaging modality for evaluating asymptomatic infants with Krabbe disease detected by NBS [<a class="bk_pop" href="#krabbe.REF.gupta.2014.792">Gupta et al 2014</a>] (see Management, <a href="#krabbe.Prevention_of_Primary_Manifestati">Prevention of Primary Manifestations</a>).</p></div></div><div id="krabbe.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p><b>Infantile-onset Krabbe disease</b> results from severe loss of galactocerebrosidase activity due to:</p><ul><li class="half_rhythm"><div>Homozygosity for the common <i>GALC</i> 30-kb <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>;</div></li><li class="half_rhythm"><div>Compound heterozygosity for either the common <i>GALC</i> 30-kb <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> and a severe <i>GALC</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (most frequently <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> or frameshift variants, but also some <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants) or two severe pathogenic variants [<a class="bk_pop" href="#krabbe.REF.tappino.2010.e1894">Tappino et al 2010</a>].</div></li></ul><p><b>Later-onset Krabbe disease.</b> The following genotypes have been observed in individuals with later-onset disease:</p><ul><li class="half_rhythm"><div><a class="figpopup" href="/books/NBK1238/table/krabbe.T.common_galc_polymorphisms_and_p/?report=objectonly" target="object" rid-figpopup="figkrabbeTcommongalcpolymorphismsandp" rid-ob="figobkrabbeTcommongalcpolymorphismsandp">p.Gly286Asp+30kb del</a> [<a class="bk_pop" href="#krabbe.REF.furuya.1997.450">Furuya et al 1997</a>, <a class="bk_pop" href="#krabbe.REF.de_gasperi.1999.256">De Gasperi et al 1999</a>]</div></li><li class="half_rhythm"><div><a class="figpopup" href="/books/NBK1238/table/krabbe.T.common_galc_polymorphisms_and_p/?report=objectonly" target="object" rid-figpopup="figkrabbeTcommongalcpolymorphismsandp" rid-ob="figobkrabbeTcommongalcpolymorphismsandp">p.Gly286Asp+p.Pro318Arg</a> [<a class="bk_pop" href="#krabbe.REF.tappino.2010.e1894">Tappino et al 2010</a>]</div></li><li class="half_rhythm"><div>p.Gly286Asp + another severe <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a></div></li><li class="half_rhythm"><div><a class="figpopup" href="/books/NBK1238/table/krabbe.T.common_galc_polymorphisms_and_p/?report=objectonly" target="object" rid-figpopup="figkrabbeTcommongalcpolymorphismsandp" rid-ob="figobkrabbeTcommongalcpolymorphismsandp">p.Thr112Ala+p.Asp187Val</a> [<a class="bk_pop" href="#krabbe.REF.luzi.1996.116">Luzi et al 1996</a>]</div></li><li class="half_rhythm"><div><a class="figpopup" href="/books/NBK1238/table/krabbe.T.common_galc_polymorphisms_and_p/?report=objectonly" target="object" rid-figpopup="figkrabbeTcommongalcpolymorphismsandp" rid-ob="figobkrabbeTcommongalcpolymorphismsandp">p.Leu634Ser</a> + another severe <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> or <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> p.Leu634Ser [<a class="bk_pop" href="#krabbe.REF.hossain.2014.144">Hossain et al 2014</a>, <a class="bk_pop" href="#krabbe.REF.zhang.2018.174">Zhang et al 2018</a>]</div></li></ul><p>The <a class="figpopup" href="/books/NBK1238/table/krabbe.T.common_galc_polymorphisms_and_p/?report=objectonly" target="object" rid-figpopup="figkrabbeTcommongalcpolymorphismsandp" rid-ob="figobkrabbeTcommongalcpolymorphismsandp">p.Gly57Ser</a> variant, a <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a> common in Catania, Italy, is associated with late-onset Krabbe disease in both the <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> and <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> states [<a class="bk_pop" href="#krabbe.REF.lissens.2007.742">Lissens et al 2007</a>].</p><p>Note that although p.Gly286Asp has been observed in individuals with a milder <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>, to date it is not possible to predict the clinical course in a given individual.</p></div><div id="krabbe.Nomenclature"><h3>Nomenclature</h3><p>The protein encoded by <i>GALC</i> is termed galactocerebrosidase in UniProt, the standard reference for <i>GeneReviews</i> (see <a href="/books/NBK1238/#krabbe.molgen.TA">Table A</a>). Because additional terms for this protein are used in the published literature, Krabbe disease may also be referred to as:</p><ul><li class="half_rhythm"><div>Galactosylceramidase deficiency</div></li><li class="half_rhythm"><div>Galactosylcerebrosidase deficiency</div></li><li class="half_rhythm"><div>&#x003b2;-galactocerebrosidase deficiency</div></li></ul></div><div id="krabbe.Prevalence"><h3>Prevalence</h3><p>Krabbe disease occurs in approximately one in 250,000 births in the United States [<a class="bk_pop" href="#krabbe.REF.barczykowski.2012.2835">Barczykowski et al 2012</a>] and approximately one in 100,000 births in Europe [<a class="bk_pop" href="#krabbe.REF.wenger.2013">Wenger et al 2013</a>]; with the median prevalence varying widely between countries [<a class="bk_pop" href="#krabbe.REF.tappino.2010.e1894">Tappino et al 2010</a>].</p><p>A very high incidence of Krabbe disease is found in a Druze community in northern Israel and two Muslim Arab villages located near Jerusalem where the <a class="def" href="/books/n/gene/glossary/def-item/carrier-rate/">carrier rate</a> is estimated at one in six [<a class="bk_pop" href="#krabbe.REF.rafi.1996.304">Rafi et al 1996</a>].</p></div><div id="krabbe.Genetically_Related_Allelic_Disor"><h3>Genetically Related (Allelic) Disorders</h3><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with pathogenic variants in <i>GALC</i>.</p></div></div><div id="krabbe.Differential_Diagnosis"><h2 id="_krabbe_Differential_Diagnosis_">Differential Diagnosis</h2><p>Although a history of normal development for the first few months after birth followed by psychomotor deterioration differentiates Krabbe disease from non-progressive CNS disorders of <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> or perinatal origin, it is nonetheless often difficult to differentiate Krabbe disease from other degenerative diseases. Individuals of any age with progressive deterioration of the central or peripheral nervous system should be evaluated for galactocerebrosidase (GALC) deficiency.</p><p>The following disorders, ordered by <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a>, should be considered in the differential diagnosis.</p><div id="krabbe.Autosomal_Recessive"><h3>Autosomal Recessive</h3><p><a href="/books/n/gene/mld/"><b>Arylsulfatase A deficiency</b></a>
<b>(metachromatic leukodystrophy, MLD)</b> is characterized by three clinical subtypes that can closely resemble late-onset Krabbe disease:</p><ul><li class="half_rhythm"><div>Late-infantile MLD (50%-60% of individuals) with onset between age one and three years</div></li><li class="half_rhythm"><div>Juvenile MLD (~20%-30%) with onset between age four years and sexual maturity (12-14 years)</div></li><li class="half_rhythm"><div>Adult MLD (~15%-20%) with onset after sexual maturity</div></li></ul><p>Biallelic pathogenic variants in <i>ARSA</i> are causative.</p><p><a href="/books/n/gene/tay-sachs/"><b>Hexosaminidase A deficiency</b></a> results in a group of neurodegenerative disorders caused by the intralysosomal storage of the specific glycosphingolipid, GM2 ganglioside. Tay-Sachs disease, the prototype hexosaminidase A deficiency, is characterized by loss of motor skills beginning between ages three and six months with progressive evidence of neurodegeneration, including seizures, macular cherry-red spots, and blindness. Total incapacitation and death usually occur before age four years. The juvenile, chronic, and adult-onset variants of hexosaminidase A deficiency have later onset, slower progression, and more variable neurologic findings, including progressive dystonia, spinocerebellar degeneration, motor neuron disease, and in some individuals with adult-onset disease, a bipolar form of psychosis. Biallelic pathogenic variants in <i>HEXA</i> are causative.</p><p><a href="/books/n/gene/canavan/"><b>Canavan disease</b></a><b>.</b> Neonatal/infantile (severe) Canavan disease is characterized by evidence of developmental delays by age three to five months with severe hypotonia and failure to achieve independent sitting, ambulation, or speech. Hypotonia evolves into spasticity and assistance with feeding becomes necessary. Life expectancy is usually into the second decade. Most individuals with Canavan disease have macrocephaly, which is a variable finding in individuals with Krabbe disease. MRI shows prominent involvement of subcortical white matter. Biallelic pathogenic variants in <i>ASPA</i> are causative.</p><p><b>Saposin A deficiency</b> (OMIM <a href="http://www.omim.org/entry/611722" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">611722</a>). An infant from a <a class="def" href="/books/n/gene/glossary/def-item/consanguineous/">consanguineous</a> union who demonstrated abnormal myelination resembling Krabbe disease was found to be <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the saposin A region of <i>PSAP</i>, which codes prosaposin, a heat-stable protein that interacts with the GALC enzyme to catalyze the hydrolysis of the natural lipid substrates [<a class="bk_pop" href="#krabbe.REF.spiegel.2005.160">Spiegel et al 2005</a>]. Saposin A deficiency may also be associated with reduced GALC enzyme activity and elevated psychosine concentrations. Biallelic pathogenic variants in <i>PSAP</i> are causative.</p></div><div id="krabbe.XLinked"><h3>X-Linked</h3><p><a href="/books/n/gene/x-ald/"><b>X-linked adrenoleukodystrophy</b></a>
<b>(X-ALD)</b> affects the nervous system white matter and the adrenal cortex. The childhood cerebral form of X-ALD is in the differential diagnosis of Krabbe disease. It manifests most commonly between age four and eight years. It initially resembles attention deficit disorder; progressive impairment of cognition, behavior, vision, hearing, and motor function follow the initial symptoms and often lead to total disability within two years. A <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> <i>ABCD1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is causative.</p><p><b>Pelizaeus-Merzbacher disease (PMD)</b> is part of the phenotypic spectrum of <a href="/books/n/gene/pmd/"><i>PLP1</i>-related disorders</a> of central nervous system myelin formation. The phenotypes that can be observed in males with this disorder range from PMD to spastic paraplegia 2 (SPG2); a wide range of phenotypes can be observed in members of the same family. PMD typically manifests in infancy or early childhood with nystagmus, hypotonia, and cognitive impairment and progresses to severe spasticity and ataxia. Life span is shortened. A <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> <i>PLP1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is causative.</p></div><div id="krabbe.Autosomal_Dominant"><h3>Autosomal Dominant</h3><p><a href="/books/n/gene/alexander/"><b>Alexander disease</b></a> is a progressive disorder of cerebral white matter that predominantly affects infants and children and has variable life expectancy. The later-onset forms present with a slower clinical course. The infantile form comprises about 42% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, the juvenile form about 22%, and the adult form about 33%. A neonatal form is also recognized. The neonatal form leads to severe disability or death within two years. The infantile form presents in the first two years of life typically with progressive psychomotor retardation with loss of developmental milestones, megalencephaly, frontal bossing, and seizures. Affected individuals survive a few weeks to several years. The juvenile form usually presents between age four and ten years, occasionally in the mid-teens. Survival is variable, ranging from the early teens to the 20s-30s. Affected individuals can present with bulbar/pseudobulbar signs, poor coordination (ataxia), gradual loss of intellectual function, seizures, normocephaly or megalencephaly, and breathing problems. A <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>GFAP</i> is causative.</p><p><a href="/books/n/gene/lad-ad/"><b>Autosomal dominant leukodystrophy with dysautonomia</b></a> is a slowly progressive disorder of central nervous system white matter characterized by onset of autonomic dysfunction in the fourth to fifth decade, followed in months to years by pyramidal and cerebellar involvement. Autonomic dysfunction can include bladder dysfunction, constipation, postural hypotension, feeding difficulties, erectile dysfunction, and (less often) impaired sweating. Pyramidal signs are often more prominent in the lower extremities (i.e., spastic weakness, hypertonia, clonus, brisk deep tendon reflexes, and bilateral Babinski signs). Cerebellar signs typically appear at the same time as the pyramidal signs and can include gait ataxia, dysdiadochokinesia, intention tremor, dysmetria, and nystagmus. Although cognitive function is usually preserved or only mildly impaired early in the disease course, dementia and psychiatric manifestations can occur as late manifestations. Affected individuals may survive for decades after onset. Either an <i>LMNB1</i>
<a href="https://www.ncbi.nlm.nih.gov/books/n/gene/glossary/def-item/duplication/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">duplication</a> or (more rarely) a large <a href="https://www.ncbi.nlm.nih.gov/books/n/gene/glossary/def-item/heterozygous/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">heterozygous</a>
<a href="https://www.ncbi.nlm.nih.gov/books/n/gene/glossary/def-item/deletion/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">deletion</a> upstream of the <i>LMNB1</i> promoter is causative.</p></div></div><div id="krabbe.Management"><h2 id="_krabbe_Management_">Management</h2><div id="krabbe.Evaluations_Following_Initial_Dia"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs of <b>a symptomatic individual</b>
<b>diagnosed with Krabbe disease</b> (i.e., <a href="#krabbe.Scenario_1_1">Scenario 1</a>), the evaluations summarized in this section (if not performed as part of the evaluation that led to the diagnosis) are recommended:</p><ul><li class="half_rhythm"><div>Neurologic and developmental examination</div></li><li class="half_rhythm"><div>Brain stem auditory evoked response to assess hearing and auditory neuropathy</div></li><li class="half_rhythm"><div>Brain MRI (DTI preferred) to understand disease progression and anticipate care needs (e.g., atrophy of brain stem is likely associated with apnea and temperature instability).</div></li><li class="half_rhythm"><div>Nerve conduction velocity to help understand the peripheral nerve involvement and development of muscle weakness</div></li><li class="half_rhythm"><div>Visual evoked potential to help understand the best approach to visual and developmental therapy</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="krabbe.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p><b>Symptomatic individual.</b> For a child younger than age six months who is in Stage II or III of infantile-onset Krabbe disease (see <a href="#krabbe.Clinical_Description">Clinical Description</a>), treatment is supportive and focused on increasing the quality of life and avoiding complications (<a class="figpopup" href="/books/NBK1238/table/krabbe.T.treatment_of_manifestations_in/?report=objectonly" target="object" rid-figpopup="figkrabbeTtreatmentofmanifestationsin" rid-ob="figobkrabbeTtreatmentofmanifestationsin">Table 2</a>) [<a class="bk_pop" href="#krabbe.REF.escolar.2016.1118">Escolar et al 2016</a>].</p><div id="krabbe.T.treatment_of_manifestations_in" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Treatment of Manifestations in Individuals with Krabbe Disease Who Have NOT Undergone Hematopoietic Stem Cell Transplantation (HSCT)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1238/table/krabbe.T.treatment_of_manifestations_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__krabbe.T.treatment_of_manifestations_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_krabbe.T.treatment_of_manifestations_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">System</th><th id="hd_h_krabbe.T.treatment_of_manifestations_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Manifestation</th><th id="hd_h_krabbe.T.treatment_of_manifestations_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Treatment</th></tr></thead><tbody><tr><td headers="hd_h_krabbe.T.treatment_of_manifestations_in_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Gastrointestinal</b></td><td headers="hd_h_krabbe.T.treatment_of_manifestations_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Vomiting &#x00026; gastroesophageal reflux disease (GERD)</td><td headers="hd_h_krabbe.T.treatment_of_manifestations_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><ul><li class="half_rhythm"><div>Maintainence of upright positioning during &#x00026; after feeding</div></li><li class="half_rhythm"><div>Consideration of proton pump inhibitors in those age &#x0003e;1 yr</div></li><li class="half_rhythm"><div>Nissen fundoplication w/gastrostomy tube (G-tube) placement.</div></li></ul>
</td></tr><tr><td headers="hd_h_krabbe.T.treatment_of_manifestations_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Dysphagia</td><td headers="hd_h_krabbe.T.treatment_of_manifestations_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><ul><li class="half_rhythm"><div>Modifying texture &#x00026; thickness of foods using commercial thickening agents can help w/swallowing difficulties.</div></li><li class="half_rhythm"><div>Swallowing ability may be improved by providing tiny tastes of food or juice several times per day in non-feeders.</div></li><li class="half_rhythm"><div>Consideration of nasogastric tube or gastric tube placement</div></li></ul>
</td></tr><tr><td headers="hd_h_krabbe.T.treatment_of_manifestations_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Constipation</td><td headers="hd_h_krabbe.T.treatment_of_manifestations_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><ul><li class="half_rhythm"><div>Maintain appropriate fluid intake.</div></li><li class="half_rhythm"><div>Consideration of osmotic laxatives &#x00026;/or use of stimulant medication in those w/refractory constipation</div></li></ul>
</td></tr><tr><td headers="hd_h_krabbe.T.treatment_of_manifestations_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Neurologic</b></td><td headers="hd_h_krabbe.T.treatment_of_manifestations_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Spasticity</td><td headers="hd_h_krabbe.T.treatment_of_manifestations_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><ul><li class="half_rhythm"><div>Baclofen &#x00026; clonazepam may improve global spasticity</div></li><li class="half_rhythm"><div>Botox injections at specific sites may be considered; spasticity typically decreases for 3-5 mos after each injection.</div></li></ul>
</td></tr><tr><td headers="hd_h_krabbe.T.treatment_of_manifestations_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Neuropathic pain; seizures</td><td headers="hd_h_krabbe.T.treatment_of_manifestations_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><ul><li class="half_rhythm"><div>Standard anti-pileptic medications; monotherapy is preferred, if possible.</div></li><li class="half_rhythm"><div>Gabapentin may decrease neuropathic pain &#x00026; can be used for control of seizures in some.</div></li></ul>
</td></tr><tr><td headers="hd_h_krabbe.T.treatment_of_manifestations_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Musculoskeletal</b></td><td headers="hd_h_krabbe.T.treatment_of_manifestations_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Contractures</td><td headers="hd_h_krabbe.T.treatment_of_manifestations_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><ul><li class="half_rhythm"><div>Positioning devices (wedges, rolls, and cushions) to decrease spasticity &#x00026; prevent contractures</div></li><li class="half_rhythm"><div>Physical therapy</div></li></ul>
</td></tr><tr><td headers="hd_h_krabbe.T.treatment_of_manifestations_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Respiratory</b></td><td headers="hd_h_krabbe.T.treatment_of_manifestations_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Excessive airway secretions</td><td headers="hd_h_krabbe.T.treatment_of_manifestations_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><ul><li class="half_rhythm"><div>Chest physiotherapy</div></li><li class="half_rhythm"><div>Postural drainage</div></li><li class="half_rhythm"><div>Suctioning device</div></li></ul>
</td></tr><tr><td headers="hd_h_krabbe.T.treatment_of_manifestations_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Genitourinary</b></td><td headers="hd_h_krabbe.T.treatment_of_manifestations_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Urinary tract infections</td><td headers="hd_h_krabbe.T.treatment_of_manifestations_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><ul><li class="half_rhythm"><div>Bladder massage (Crede maneuver) to encourage complete bladder emptying</div></li><li class="half_rhythm"><div>Intermittent catheterization</div></li></ul>
</td></tr><tr><td headers="hd_h_krabbe.T.treatment_of_manifestations_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Eyes</b></td><td headers="hd_h_krabbe.T.treatment_of_manifestations_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Delayed pupillary response, difficulty w/upward gaze &#x00026; palpebral weakness</td><td headers="hd_h_krabbe.T.treatment_of_manifestations_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_krabbe.T.treatment_of_manifestations_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Corneal ulcers</td><td headers="hd_h_krabbe.T.treatment_of_manifestations_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><ul><li class="half_rhythm"><div>Dark glasses to help reduce photophobia</div></li><li class="half_rhythm"><div>Eye lubricants or protective ointments</div></li></ul>
</td></tr><tr><td headers="hd_h_krabbe.T.treatment_of_manifestations_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Dental</b></td><td headers="hd_h_krabbe.T.treatment_of_manifestations_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Delayed dentition</td><td headers="hd_h_krabbe.T.treatment_of_manifestations_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Table adapted from <a class="bk_pop" href="#krabbe.REF.escolar.2016.1118">Escolar et al [2016]</a></p></div></dd></dl></div></div></div><p><b>Older individuals with mild manifestations.</b> Treatment (based on standard practice) is tailored to the manifestations in each individual.</p></div><div id="krabbe.Prevention_of_Primary_Manifestati"><h3>Prevention of Primary Manifestations</h3><p><a class="bk_pop" href="#krabbe.REF.escolar.2005.2069">Escolar et al [2005]</a> reported that all 11 asymptomatic newborns (diagnosed prenatally or shortly after birth because of a family history of Krabbe disease) who underwent HSCT between ages 12 and 44 days had stable engraftment of donor hematopoietic stem cells that provided a long-term source of GALC enzyme. Follow up over four months to six years has thus far revealed that while most children had normal cognitive ability and receptive language, they eventually developed speech and motor difficulties (including spasticity).</p><p><a class="bk_pop" href="#krabbe.REF.wasserstein.2016.1235">Wasserstein et al [2016]</a> reported outcomes for five infants from four families detected by the New York State <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> program. Two of the five were sibs. All but the first-born in the sib pair underwent HSCT between days 24 and 41 of life. Outcomes for the four who underwent HSCT were not ideal, likely due to disease severity at the time of the transplantation. More recently, several newborns identified through other state newborn screening programs have had more positive outcomes [Orsini, personal observation].</p><p><a class="bk_pop" href="#krabbe.REF.wright.2017.1365">Wright et al [2017]</a> reported a 15-year study of outcomes for 18 individuals presumed to have a form of infantile-onset Krabbe disease who underwent HSCT in the first seven weeks of life. Following early HSCT, the long-term outcome of motor function reflected the severity of corticospinal tract involvement at birth. Peripheral nerve disease progressed with time, causing severe muscular atrophy and scoliosis. Compared to children not treated as babies, those treated early with HSCT can live relatively normal lives with variable motor disabilities until the teen years when the disease may progress. Mortality was 25%, slightly less than general mortality for non-malignant diseases. Outcomes following HSCT vary widely: some individuals live completely normal lives, whereas others are disabled (ranging from reliance on walkers for mobility to quadriplegia). The outcomes depend on how early disease is detected, the severity of disease, and progression of the disease prior to treatment.</p><p><b>Asymptomatic newborns with infantile-onset Krabbe disease.</b> Consensus guidelines recommend that asymptomatic newborns identified by either prenatal/neonatal evaluation because of a positive family history of Krabbe disease (see <a href="#krabbe.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a>) or an abnormal <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> result undergo additional testing to identify those with infantile-onset Krabbe disease (see Establishing the Diagnosis, <a href="#krabbe.Scenario_2_1">Scenario 2</a>). Those with laboratory findings consistent with infantile-onset Krabbe disease are thus candidates for HSCT before age 14 days [<a class="bk_pop" href="#krabbe.REF.kwon.2018.30">Kwon et al 2018</a>].</p><p><b>Asymptomatic newborns with abnormal <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> results presumed to be at risk for later-onset Krabbe disease.</b> No guidelines have been published for monitoring these at-risk individuals and to date there are no validated markers that can predict later disease onset [<a class="bk_pop" href="#krabbe.REF.wasserstein.2016.1235">Wasserstein et al 2016</a>].</p><p><b>Symptomatic individuals with later-onset Krabbe disease</b>. The manifestations of Krabbe disease progress more slowly; thus, individuals with later-onset Krabbe disease diagnosed early enough in the disease course may benefit from HSCT. In a single report by <a class="bk_pop" href="#krabbe.REF.laule.2018.252">Laule et al [2018]</a> treatment was found to arrest demyelination and axonal loss.</p></div><div id="krabbe.Prevention_of_Secondary_Complicat"><h3>Prevention of Secondary Complications</h3><p><b>Symptomatic individuals with Krabbe disease</b></p><ul><li class="half_rhythm"><div>Physical therapy can improve strength, mobility, flexibility, and function.</div></li><li class="half_rhythm"><div>Erythromycin may be useful as a prophylactic antibiotic and may also improve gastrointestinal motility.</div></li><li class="half_rhythm"><div>Annual influenza vaccination is recommended [<a class="bk_pop" href="#krabbe.REF.anderson.2014.370">Anderson et al 2014</a>], although other routine vaccinations are typically avoided (see <a href="#krabbe.AgentsCircumstances_to_Avoid">Agents/Circumstances to Avoid</a>).</div></li></ul></div><div id="krabbe.Surveillance"><h3>Surveillance</h3><p><b>Symptomatic individuals with Krabbe disease</b></p><p>Monitor for development of:</p><ul><li class="half_rhythm"><div>Hydrocephalus and need for VP shunt</div></li><li class="half_rhythm"><div>Scoliosis, hip subluxation, and osteopenia (via DEXA scan)</div></li><li class="half_rhythm"><div>Decreased vision and corneal ulcerations</div></li><li class="half_rhythm"><div>Swallowing difficulties and chronic microaspiration (via modified barium swallow)</div></li></ul></div><div id="krabbe.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p><b>Symptomatic individuals with Krabbe disease</b></p><ul><li class="half_rhythm"><div>Atypical antipsychotics and multiple medications for seizures [Author, personal experience], which can: overly sedate patients, further affecting cognition; affect respiratory drive; and accelerate the neurodegenerative cascade</div></li><li class="half_rhythm"><div>Routine childhood vaccinations, including live virus vaccines, as the resulting immune response may accelerate disease progression [<a class="bk_pop" href="#krabbe.REF.escolar.2016.1118">Escolar et al 2016</a>]</div></li><li class="half_rhythm"><div>Prolonged indwelling catheters for urinary retention due to the high risk of infection</div></li></ul></div><div id="krabbe.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>Couples who have had one child with molecularly confirmed infantile-onset Krabbe disease may choose prenatal <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> in subsequent pregnancies so that newborns with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>GALC</i> pathogenic variants can be promptly tested (see Establishing the Diagnosis, <a href="#krabbe.Scenario_2_1">Scenario 2</a>) and &#x02013; if appropriate &#x02013; referred for HSCT (see <a href="#krabbe.Prevention_of_Primary_Manifestati">Prevention of Primary Manifestations)</a>.</p><p>Note that because of <a class="def" href="/books/n/gene/glossary/def-item/intrafamilial-variability/">intrafamilial variability</a>, sibs of an individual with later-onset Krabbe disease may develop the disease at a much earlier age.</p><p>See <a href="#krabbe.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="krabbe.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Studies are being conducted using well-characterized animal models to investigate other treatment options including enzyme replacement therapy, neural stem cell transplantation, substrate reduction therapy, and chemical chaperone therapy. To date experimental "combination therapies" (HSCT together with <a class="def" href="/books/n/gene/glossary/def-item/gene-therapy/">gene therapy</a>) in the GALC-deficient murine model have demonstrated the potential to further advance treatment of GALC deficiency by synergistically increasing the life span of the treated mice [<a class="bk_pop" href="#krabbe.REF.reddy.2013.e64647">Reddy et al 2013</a>, <a class="bk_pop" href="#krabbe.REF.rafi.2015.1681">Rafi et al 2015</a>, <a class="bk_pop" href="#krabbe.REF.ungari.2015.15038">Ungari et al 2015</a>].</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="krabbe.Genetic_Counseling"><h2 id="_krabbe_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="krabbe.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Krabbe disease is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="krabbe.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual are obligate heterozygotes (i.e., carriers of one <i>GALC</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with later-onset Krabbe disease.</b> The offspring of an individual with later-onset Krabbe disease are obligate heterozygotes (carriers) for a <i>GALC</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents (aunts and uncles of the proband) and each grandparent is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of a <i>GALC</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="krabbe.Heterozygote_Carrier_Detection"><h3>Heterozygote (Carrier) Detection</h3><p><b>At-risk family members.</b> Carrier testing for at-risk relatives requires prior identification of the <i>GALC</i> pathogenic variants in the family.</p></div><div id="krabbe.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#krabbe.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="krabbe.Prenatal_Testing_and_Preimplantat"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p><b>Molecular genetic testing.</b> Once the <i>GALC</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p><p><b>Biochemical genetic testing.</b> Prenatal testing by GALC enzyme testing is not offered in the United States.</p></div></div><div id="krabbe.Resources"><h2 id="_krabbe_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Hunter's Hope Foundation</b></div><div>6368 West Quaker Street</div><div>PO Box 643</div><div>Orchard Park NY 14127</div><div><b>Phone:</b> 877-984-4673 (toll-free); 716-667-1200</div><div><b>Fax:</b> 716-667-1212</div><div><b>Email:</b> info@huntershope.org</div><div><a href="http://www.huntershope.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.huntershope.org</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition=krabbedisease" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Krabbe disease</a></div></li><li class="half_rhythm"><div><b>Partners for Krabbe Research</b></div><div><a href="http://krabbes.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.krabbes.org</a></div></li><li class="half_rhythm"><div><b>The Legacy of Angels Foundation</b></div><div>PO Box 1014</div><div>Prior Lake MN 55372</div><div><b>Email:</b> info@tloaf.org</div><div><a href="http://tloaf.org/krabbe-disease" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Krabbe Disease</a></div></li><li class="half_rhythm"><div><b>United Leukodystrophy Foundation (ULF)</b></div><div>224 North Second Street</div><div>Suite 2</div><div>DeKalb IL 60115</div><div><b>Phone:</b> 800-728-5483 (toll-free); 815-748-3211</div><div><b>Fax:</b> 815-748-0844</div><div><b>Email:</b> office@ulf.org</div><div><a href="http://www.ulf.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ulf.org</a></div></li><li class="half_rhythm"><div><b>Hunter James Kelly Research Institute Registry</b></div><div><b>Phone:</b> 716-667-1200</div><div><b>Email:</b> info@huntershope.org</div><div><a href="https://www.huntershope.org/research/hunter-james-kelly-research-institute/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Hunter James Kelly Research Institute Registry</a></div></li><li class="half_rhythm"><div><b>Myelin Disorders Bioregistry Project</b></div><div><b>Email:</b> myelindisorders@cnmc.org</div><div><a href="https://www.chop.edu/research/myelin-disorders-biorepository-project" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Myelin Disorders Bioregistry Project</a></div></li></ul></div><div id="krabbe.Molecular_Genetics"><h2 id="_krabbe_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="krabbe.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Krabbe Disease: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1238/table/krabbe.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__krabbe.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_krabbe.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_krabbe.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_krabbe.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_krabbe.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_krabbe.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_krabbe.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_krabbe.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/2581" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>GALC</i></a></td><td headers="hd_b_krabbe.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=2581" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">14q31<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_krabbe.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P54803" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Galactocerebrosidase</a></td><td headers="hd_b_krabbe.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/GALC" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">GALC database</a><br /><a href="http://bipmed.iqm.unicamp.br/snparray/genes/GALC" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">BIPMed SNP Array - GALC</a><br /><a href="http://proteomics.bio21.unimelb.edu.au/lovd/genes/GALC" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">GALC homepage - LOVD - Australian Human Variome Project</a></td><td headers="hd_b_krabbe.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=GALC" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">GALC</a></td><td headers="hd_b_krabbe.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=GALC[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">GALC</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="krabbe.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="krabbe.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Krabbe Disease (<a href="/omim/245200,606890" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1238/table/krabbe.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__krabbe.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/245200" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">245200</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">KRABBE DISEASE</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/606890" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">606890</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">GALACTOSYLCERAMIDASE; GALC</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>GALC</i> is approximately 57 kb in length with 17 exons that code for a 685-amino-acid precursor protein that is processed &#x02013; after cleavage of the 16-amino-acid signal peptide &#x02013; into a protein of 669 amino acids. Historic nomenclature numbered amino acids beginning at -16; therefore, codon numbers in older references [<a class="bk_pop" href="#krabbe.REF.wenger.1997.268">Wenger et al 1997</a>] may differ from current standard nomenclature by 16 amino acids.</p><p><b>Benign variants.</b> Three common <i>GALC</i> variants (p.Arg184Cys, p.Asp248Asn, and p.Ile562Thr) attenuate GALC enzyme activity [<a class="bk_pop" href="#krabbe.REF.saavedramatiz.2016.1076">Saavedra-Matiz et al 2016</a>]. Although not disease-causing, their presence complicates the interpretation of the clinical significance of low enzyme activity. However, p.Ile562Thr [legacy: p.Ile546Thr] has been shown to be disease causing when <i>in cis</i> with another mild <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, e.g. p.Thr112Ala [legacy: p.Thr96Ala] [<a class="bk_pop" href="#krabbe.REF.wenger.2014.307">Wenger et al 2014</a>, <a class="bk_pop" href="#krabbe.REF.saavedramatiz.2016.1076">Saavedra-Matiz et al 2016</a>]. Furthermore, other non-disease-causing variants <i>reduce</i> in vitro enzyme activity measurements detected by <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> in asymptomatic individuals.</p><p><b>Pathogenic variants.</b> More than 200 pathogenic variants including <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, frameshift, <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a>, and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants have been identified. It is often not possible to predict the clinical presentation from the location or type of variant.</p><p>The 30-kb <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>, the most common <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, which begins within the large <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 10 and extends beyond the end of the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>, accounts for approximately 45% of pathogenic variants in persons of European ancestry. This deletion comprises a significant proportion of pathogenic variants in individuals of Mexican, Pakistani, and Indian heritage. When in the <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> state or in the <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> state with another severe pathogenic variant this deletion results in infantile-onset Krabbe disease. Thus far, all individuals with Krabbe disease identified through <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> have a least one copy of the deletion.</p><p>Several other pathogenic variants associated with infantile-onset Krabbe disease (p.Thr529Met, p.Tyr567Ser, and c.1472delA) make up another 15% of the abnormal alleles in individuals of European ancestry [<a class="bk_pop" href="#krabbe.REF.kleijer.1997.587">Kleijer et al 1997</a>, <a class="bk_pop" href="#krabbe.REF.wenger.1997.268">Wenger et al 1997</a>].</p><p>A 7.4-kb <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> has also been observed in multiple patients.</p><p>The <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> p.Gly286Asp results in the later-onset form of GALC deficiency, even when present with the 30-kb <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> as the second <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>.</p><p>A <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a> common in Catania, Italy, p.Gly57Ser, is associated with later-onset Krabbe disease in both the <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> and <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> states [<a class="bk_pop" href="#krabbe.REF.lissens.2007.742">Lissens et al 2007</a>]. In general the genotypes of individuals with Krabbe disease are complex, with combinations of benign variants and pathogenic variants.</p><p>When variants of <a class="def" href="/books/n/gene/glossary/def-item/unknown-significance/">unknown significance</a> are identified, elevated psychosine (within reference range for infantile-onset Krabbe disease) and low GALC activity are suggestive findings of infantile-onset Krabbe disease.</p><p>A more complete catalog of reported <i>GALC</i> variants is available in <a class="bk_pop" href="#krabbe.REF.wenger.2013">Wenger et al [2013]</a>.</p><div id="krabbe.T.common_galc_polymorphisms_and_p" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Common <i>GALC</i> Polymorphisms and Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1238/table/krabbe.T.common_galc_polymorphisms_and_p/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__krabbe.T.common_galc_polymorphisms_and_p_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_krabbe.T.common_galc_polymorphisms_and_p_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variant<br />Classification</th><th id="hd_h_krabbe.T.common_galc_polymorphisms_and_p_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change<br />(Alias&#x000a0;<sup>1)</sup></th><th id="hd_h_krabbe.T.common_galc_polymorphisms_and_p_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_krabbe.T.common_galc_polymorphisms_and_p_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_krabbe.T.common_galc_polymorphisms_and_p_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Benign</b></td><td headers="hd_h_krabbe.T.common_galc_polymorphisms_and_p_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.550C&#x0003e;T</td><td headers="hd_h_krabbe.T.common_galc_polymorphisms_and_p_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg184Cys<br />(p.Arg168Cys)</td><td headers="hd_h_krabbe.T.common_galc_polymorphisms_and_p_1_1_1_4" rowspan="13" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_000153.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000153<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/protein/NP_000144.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000144<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_krabbe.T.common_galc_polymorphisms_and_p_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.742G&#x0003e;A</td><td headers="hd_h_krabbe.T.common_galc_polymorphisms_and_p_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asp248Asn<br />(p.Asp232Asn)</td></tr><tr><td headers="hd_h_krabbe.T.common_galc_polymorphisms_and_p_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.1685T&#x0003e;C</td><td headers="hd_h_krabbe.T.common_galc_polymorphisms_and_p_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ile562Thr<br />(p.Ile546Thr)</td></tr><tr><td headers="hd_h_krabbe.T.common_galc_polymorphisms_and_p_1_1_1_1" rowspan="10" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Pathogenic</b></td><td headers="hd_h_krabbe.T.common_galc_polymorphisms_and_p_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(30-kb <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>)&#x000a0;<sup>2</sup></td><td headers="hd_h_krabbe.T.common_galc_polymorphisms_and_p_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_krabbe.T.common_galc_polymorphisms_and_p_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.169G&#x0003e;A<br />(121G&#x0003e;A)</td><td headers="hd_h_krabbe.T.common_galc_polymorphisms_and_p_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly57Ser<br />(Gly41Ser)</td></tr><tr><td headers="hd_h_krabbe.T.common_galc_polymorphisms_and_p_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.334A&#x0003e;G<br />(286A&#x0003e;G)</td><td headers="hd_h_krabbe.T.common_galc_polymorphisms_and_p_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Thr112Ala<br />(Thr96Ala)</td></tr><tr><td headers="hd_h_krabbe.T.common_galc_polymorphisms_and_p_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.560A&#x0003e;T<br />(512A&#x0003e;T)</td><td headers="hd_h_krabbe.T.common_galc_polymorphisms_and_p_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asp187Val<br />(Asp171Val)</td></tr><tr><td headers="hd_h_krabbe.T.common_galc_polymorphisms_and_p_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.857G&#x0003e;A<br />(809G&#x0003e;A)</td><td headers="hd_h_krabbe.T.common_galc_polymorphisms_and_p_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly286Asp&#x000a0;<sup>3</sup><br />(Gly270Asp)</td></tr><tr><td headers="hd_h_krabbe.T.common_galc_polymorphisms_and_p_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.953C&#x0003e;T<br />(944C&#x0003e;T)</td><td headers="hd_h_krabbe.T.common_galc_polymorphisms_and_p_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Pro318Arg<br />(p.Gly302Arg)</td></tr><tr><td headers="hd_h_krabbe.T.common_galc_polymorphisms_and_p_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.1472delA<br />(1424delA)</td><td headers="hd_h_krabbe.T.common_galc_polymorphisms_and_p_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Lys491ArgfsTer62</td></tr><tr><td headers="hd_h_krabbe.T.common_galc_polymorphisms_and_p_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.1586C&#x0003e;T<br />(1538C&#x0003e;T)</td><td headers="hd_h_krabbe.T.common_galc_polymorphisms_and_p_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Thr529Met<br />(Thr513Met)</td></tr><tr><td headers="hd_h_krabbe.T.common_galc_polymorphisms_and_p_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.1700A&#x0003e;C<br />(1652A&#x0003e;C)</td><td headers="hd_h_krabbe.T.common_galc_polymorphisms_and_p_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Tyr567Ser<br />(Tyr551Ser)</td></tr><tr><td headers="hd_h_krabbe.T.common_galc_polymorphisms_and_p_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.1901T&#x0003e;C<br />(1853T&#x0003e;C)</td><td headers="hd_h_krabbe.T.common_galc_polymorphisms_and_p_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Leu634Ser&#x000a0;<sup>4</sup><br />(Leu618Ser)</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature. <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>).</p></div></dd><dt>1. </dt><dd><div id="krabbe.TF.3.1"><p class="no_margin">Historic variant designations that do not conform to current naming conventions. In this instance, the variant designations conform to the <a class="def" href="/books/n/gene/glossary/def-item/cdna/">cDNA</a> reference sequence in the HGMD database (see <a href="/books/NBK1238/#krabbe.molgen.TA">Table A</a>) and some publications.</p></div></dd><dt>2. </dt><dd><div id="krabbe.TF.3.2"><p class="no_margin">Begins in <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 10 and deletes the remainder of the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and additional contiguous sequences</p></div></dd><dt>3. </dt><dd><div id="krabbe.TF.3.3"><p class="no_margin">One copy of this <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> together with another <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> results in late-onset disease.</p></div></dd><dt>4. </dt><dd><div id="krabbe.TF.3.4"><p class="no_margin">One copy of this <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> together with another severe allele in the <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> state is associated with late-onset disease [<a class="bk_pop" href="#krabbe.REF.hossain.2014.144">Hossain et al 2014</a>, <a class="bk_pop" href="#krabbe.REF.zhang.2018.174">Zhang et al 2018</a>].</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The 80-kd precursor protein contains six potential glycosylation sites and is proteolytically cut into the active 50-kd and 30-kd subunits. These subunits are not active individually, but aggregate into a very high hydrophobic molecular-weight complex.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Loss or significant reduction of galactosylceramidase function results in Krabbe disease.</p></div><div id="krabbe.References"><h2 id="_krabbe_References_">References</h2><div id="krabbe.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.anderson.2014.370">Anderson HM, Wilkes J, Korgenski EK, Pulsipher MA, Blaschke AJ, Hersh AL, Srivastava R, Bonkowsky JL. Preventable infections in children with leukodystrophy. <span><span class="ref-journal">Ann Clin Transl Neurol. </span>2014;<span class="ref-vol">1</span>:370–4.</span> [<a href="/pmc/articles/PMC4063358/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4063358</span></a>] [<a href="/pubmed/24955379" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24955379</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.barczykowski.2012.2835">Barczykowski AL, Foss AH, Duffner PK, Yan L, Carter RL. Death rates in the U.S. due to Krabbe disease and related leukodystrophy and lysosomal storage diseases. <span><span class="ref-journal">Am J Med Genet A. </span>2012;<span class="ref-vol">158A</span>:2835–42.</span> [<a href="/pubmed/22991292" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22991292</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.bascou.2018.126">Bascou N, DeRenzo A, Poe MD, Escolar ML. A prospective natural history study of Krabbe disease in a patient cohort with onset between 6 months and 3 years of life. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2018;<span class="ref-vol">13</span>:126.</span> [<a href="/pmc/articles/PMC6083585/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6083585</span></a>] [<a href="/pubmed/30089515" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30089515</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.debs.2013.859">Debs R, Froissart R, Aubourg P, Papeix C, Douillard C, Degos B, Fontaine B, Audoin B, Lacour A, Said G, Vanier MT, Sedel F. Krabbe disease in adults: phenotypic and genotypic update from a series of 11 cases and a review. <span><span class="ref-journal">J Inherit Metab Dis. </span>2013;<span class="ref-vol">36</span>:859–68.</span> [<a href="/pubmed/23197103" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23197103</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.de_gasperi.1999.256">De Gasperi R, Gama Sosa MA, Sartorato E, Battistini S, Raghavan S, Kolodny EH. Molecular basis of late-life globoid cell leukodystrophy. <span><span class="ref-journal">Hum Mutat. </span>1999;<span class="ref-vol">14</span>:256–62.</span> [<a href="/pubmed/10477434" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10477434</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.escolar.2017.271">Escolar ML, Kiely BT, Shawgo E, Hong X, Gelb MH, Orsini JJ, Matern D, Poe MD. Psychosine, a marker of Krabbe phenotype and treatment effect. <span><span class="ref-journal">Mol Genet Metab. </span>2017;<span class="ref-vol">121</span>:271–8.</span> [<a href="/pmc/articles/PMC5548593/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5548593</span></a>] [<a href="/pubmed/28579020" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28579020</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.escolar.2005.2069">Escolar ML, Poe MD, Provenzale JM, Richards KC, Allison J, Wood S, Wenger DA, Pietryga D, Wall D, Champagne M, Morse R, Krivit W, Kurtzberg J. Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. <span><span class="ref-journal">N Engl J Med. </span>2005;<span class="ref-vol">352</span>:2069–81.</span> [<a href="/pubmed/15901860" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15901860</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.escolar.2016.1118">Escolar ML, West T, Dallavecchia A, Poe MD, LaPoint K. Clinical management of Krabbe disease. <span><span class="ref-journal">J Neurosci Res. </span>2016;<span class="ref-vol">94</span>:1118–25.</span> [<a href="/pubmed/27638597" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27638597</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.fiumara.2011.452">Fiumara A, Barone R, Arena A, Filocamo M, Lissens W, Pavone L, Sorge G. Krabbe leukodystrophy in a selected population with high rate of late onset forms: longer survival linked to c.121G&#x0003e;A (p.Gly41Ser) mutation. <span><span class="ref-journal">Clin Genet. </span>2011;<span class="ref-vol">80</span>:452–8.</span> [<a href="/pubmed/21070211" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21070211</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.furuya.1997.450">Furuya H, Kukita Y, Nagano S, Sakai Y, Yamashita Y, Fukuyama H, Inatomi Y, Saito Y, Koike R, Tsuji S, Fukumaki Y, Hayashi K, Kobayashi T. Adult onset globoid cell leukodystrophy (Krabbe disease): analysis of galactosylceramidase cDNA from four Japanese patients. <span><span class="ref-journal">Hum Genet. </span>1997;<span class="ref-vol">100</span>:450–6.</span> [<a href="/pubmed/9272171" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9272171</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.gupta.2014.792">Gupta A, Poe MD, Styner MA, Panigrahy A, Escolar ML. Regional differences in fiber tractography predict neurodevelopmental outcomes in neonates with infantile Krabbe disease. <span><span class="ref-journal">Neuroimage Clin. </span>2014;<span class="ref-vol">7</span>:792–8.</span> [<a href="/pmc/articles/PMC4375637/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4375637</span></a>] [<a href="/pubmed/25844309" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25844309</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.hossain.2014.144">Hossain MA, Otomo T, Saito S, Ohno K, Sakuraba H, Hamada Y, Ozono K, Sakai N. Late-onset Krabbe disease is predominant in Japan and its mutant precursor protein undergoes more effective processing than the infantile-onset form. <span><span class="ref-journal">Gene. </span>2014;<span class="ref-vol">534</span>:144–54.</span> [<a href="/pubmed/24252386" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24252386</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.husain.2004.617">Husain AM, Altuwaijri M, Aldosari M. Krabbe disease: neurophysiologic studies and MRI correlations. <span><span class="ref-journal">Neurology. </span>2004;<span class="ref-vol">63</span>:617–20.</span> [<a href="/pubmed/15326231" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15326231</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.jardim.1999.1014">Jardim LB, Giugliani R, Pires RF, Haussen S, Burin MG, Rafi MA, Wenger DA. Protracted course of Krabbe disease in an adult patient bearing a novel mutation. <span><span class="ref-journal">Arch Neurol. </span>1999;<span class="ref-vol">56</span>:1014–7.</span> [<a href="/pubmed/10448809" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10448809</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.kleijer.1997.587">Kleijer WJ, Keulemans JL, van der Kraan M, Geilen GG, van der Helm RM, Rafi MA, Luzi P, Wenger DA, Halley DJ, van Diggelen OP. Prevalent mutations in the GALC gene of patients with Krabbe disease of Dutch and other European origin. <span><span class="ref-journal">J Inherit Metab Dis. </span>1997;<span class="ref-vol">20</span>:587–94.</span> [<a href="/pubmed/9266397" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9266397</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.kolodny.1991.232">Kolodny EH, Raghavan S, Krivit W. Late-onset Krabbe disease (globoid cell leukodystrophy): clinical and biochemical features of 15 cases. <span><span class="ref-journal">Dev Neurosci. </span>1991;<span class="ref-vol">13</span>:232–9.</span> [<a href="/pubmed/1817026" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1817026</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.kornlubetzki.2003.115">Korn-Lubetzki I, Dor-Wollman T, Soffer D, Raas-Rothschild A, Hurvitz H, Nevo Y. Early peripheral nervous system manifestations of infantile Krabbe disease. <span><span class="ref-journal">Pediatr Neurol. </span>2003;<span class="ref-vol">28</span>:115–8.</span> [<a href="/pubmed/12699861" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12699861</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.kwon.2018.30">Kwon JM, Matern D, Kurtzberg J, Wrabetz L, Gelb MH, Wenger DA, Ficicioglu C, Waldman AT, Burton BK, Hopkins PV, Orsini JJ. Consensus guidelines for newborn screening, diagnosis and treatment of infantile Krabbe disease. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2018;<span class="ref-vol">13</span>:30.</span> [<a href="/pmc/articles/PMC5796396/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5796396</span></a>] [<a href="/pubmed/29391017" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29391017</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.laule.2018.252">Laule C, Vavasour IM, Shahinfard E, M&#x000e4;dler B, Zhang J, Li DKB, MacKay AL, Sirrs SM. Hematopoietic stem cell transplantation in late-onset Krabbe disease: no evidence of worsening demyelination and axonal loss 4 years post-allograft. <span><span class="ref-journal">J Neuroimaging. </span>2018;<span class="ref-vol">28</span>:252–5.</span> [<a href="/pubmed/29479774" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29479774</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.lieberman.1980.446">Lieberman JS, Oshtory M, Taylor RG, Dreyfus PM. Perinatal neuropathy as an early manifestation of Krabbe's disease. <span><span class="ref-journal">Arch Neurol. </span>1980;<span class="ref-vol">37</span>:446–7.</span> [<a href="/pubmed/6248003" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6248003</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.lissens.2007.742">Lissens W, Arena A, Seneca S, Rafi M, Sorge G, Liebars I., Wenger D, Fiumara A. A single mutation in the <em>GALC</em> gene is responsible for the majority of late onset Krabbe disease patients in the Catania (Sicily, Italy) region. <span><span class="ref-journal">Hum Mutat. </span>2007;<span class="ref-vol">28</span>:742.</span> [<a href="/pubmed/17579360" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17579360</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.luzi.1995.2335">Luzi P, Rafi MA, Wenger DA. Characterization of the large deletion in the GALC gene found in patients with Krabbe disease. <span><span class="ref-journal">Hum Mol Genet. </span>1995;<span class="ref-vol">4</span>:2335–8.</span> [<a href="/pubmed/8634707" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8634707</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.luzi.1996.116">Luzi P, Rafi MA, Wenger DA. Multiple mutations in the GALC gene in a patient with adult-onset Krabbe disease. <span><span class="ref-journal">Ann Neurol. </span>1996;<span class="ref-vol">40</span>:116–9.</span> [<a href="/pubmed/8687180" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8687180</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.minter_baerg.2018.847">Minter Baerg MM, Stoway SD, Hart J, Mott L, Peck DS, Nett SL, Eckerman JS, Lacey JM, Turgeon CT, Gavrilov D, Oglesbee D, Raymond K, Tortorelli S, Matern D, M&#x000f8;rkrid L, Rinaldo P. Precision newborn screening for lysosomal disorders. <span><span class="ref-journal">Genet Med. </span>2018;<span class="ref-vol">20</span>:847–54.</span> [<a href="/pubmed/29120458" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29120458</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.orsini.2016.239">Orsini JJ, Kay DM, Saavedra-Matiz CA, Wenger DA, Duffner PK, Erbe RW, Biski C, Martin M, Krein LM, Nichols M, Kurtzberg J, Escolar ML, Adams DJ, Arnold GL, Iglesias A, Galvin-Parton P, Kronn DF, Kwon JM, Levy PA, Pellegrino JE, Shur N, Wasserstein MP, Caggana M., New York State Krabbe Disease Consortium.  Newborn screening for Krabbe disease in New York State: the first eight years' experience. <span><span class="ref-journal">Genet Med. </span>2016;<span class="ref-vol">18</span>:239–48.</span> [<a href="/pubmed/26795590" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26795590</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.rafi.1995.1285">Rafi MA, Luzi P, Chen YQ, Wenger DA. A large deletion together with a point mutation in the GALC gene is a common mutant allele in patients with infantile Krabbe disease. <span><span class="ref-journal">Hum Mol Genet. </span>1995;<span class="ref-vol">4</span>:1285–9.</span> [<a href="/pubmed/7581365" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7581365</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.rafi.1996.304">Rafi MA, Luzi P, Zlotogora J, Wenger DA. Two different mutations are responsible for Krabbe disease in the Druze and Moslem Arab populations in Israel. <span><span class="ref-journal">Hum Genet. </span>1996;<span class="ref-vol">97</span>:304–8.</span> [<a href="/pubmed/8786069" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8786069</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.rafi.2015.1681">Rafi MA, Rao HZ, Luzi P, Wenger DA. Long-term improvements in lifespan and pathology in CNS and PNS after BMT plus one intravenous injection of AAVrh10-GALC in Twitcher mice. <span><span class="ref-journal">Mol Ther. </span>2015;<span class="ref-vol">23</span>:1681–90.</span> [<a href="/pmc/articles/PMC4817953/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4817953</span></a>] [<a href="/pubmed/26329589" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26329589</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.reddy.2013.e64647">Reddy AS, Patel JR, Vogler C, Klein RS, Sands MS. Central nervous system pathology progresses independently of KC and CXCR2 in globoid-cell leukodystrophy. <span><span class="ref-journal">PLoS One. </span>2013;<span class="ref-vol">8</span>:e64647.</span> [<a href="/pmc/articles/PMC3670857/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3670857</span></a>] [<a href="/pubmed/23755134" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23755134</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.saavedramatiz.2016.1076">Saavedra-Matiz CA, Luzi P, Nichols M, Orsini JJ, Caggana M, Wenger DA. Expression of individual mutations and haplotypes in the galactocerebrosidase gene identified by the newborn screening program in New York State and in confirmed cases of Krabbe's disease. <span><span class="ref-journal">J Neurosci Res. </span>2016;<span class="ref-vol">94</span>:1076–83.</span> [<a href="/pubmed/27638593" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27638593</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.satoh.1997.1392">Satoh JI, Tokumoto H, Kurohara K, Yukitake M, Matsui M, Kuroda Y, Yamamoto T, Furuya H, Shinnoh N, Kobayashi T, Kukita Y, Hayashi K. Adult-onset Krabbe disease with homozygous T1853C mutation in the galactocerebrosidase gene. Unusual MRI findings of corticospinal tract demyelination. <span><span class="ref-journal">Neurology. </span>1997;<span class="ref-vol">49</span>:1392–9.</span> [<a href="/pubmed/9371928" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9371928</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.shah.2011.22">Shah SS, Ebberson J, Kestenbaum LA, Hodinka RL, Zorc JJ. Age-specific reference values for cerebrospinal fluid protein concentration in neonates and young infants. <span><span class="ref-journal">J Hosp Med. </span>2011;<span class="ref-vol">6</span>:22–7.</span> [<a href="/pmc/articles/PMC2978786/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2978786</span></a>] [<a href="/pubmed/20629018" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20629018</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.siddiqi.2006.263">Siddiqi ZA, Sanders DB, Massey JM. Peripheral neuropathy in Krabbe disease: electrodiagnostic findings. <span><span class="ref-journal">Neurology. </span>2006;<span class="ref-vol">67</span>:263–7.</span> [<a href="/pubmed/16864819" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16864819</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.spiegel.2005.160">Spiegel R, Bach G, Sury V, Mengistu G, Meidan B, Shalev S, Shneor Y, Mandel H, Zeigler M. A mutation in the saposin A coding region of the prosaposin gene in an infant presenting as Krabbe disease: first report of saposin A deficiency in humans. <span><span class="ref-journal">Mol Genet Metab. </span>2005;<span class="ref-vol">84</span>:160–6.</span> [<a href="/pubmed/15773042" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15773042</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.tanner.2012.38">Tanner AK, Chin EL, Duffner PK, Hegde M. Array CGH improves detection of mutations in the GALC gene associated with Krabbe disease. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2012;<span class="ref-vol">7</span>:38.</span> [<a href="/pmc/articles/PMC3404939/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3404939</span></a>] [<a href="/pubmed/22704718" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22704718</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.tappino.2010.e1894">Tappino B, Biancheri R, Mort M, Regis S, Corsolini F, Rossi A, Stroppiano M, Lualdi S, Fiumara A, Bembi B, DiRocco M, Cooper DN, Filocamo M. Identification and characterization of 15 novel GALC gene mutations causing Krabbe disease. <span><span class="ref-journal">Hum Mutat. </span>2010;<span class="ref-vol">31</span>:E1894–914.</span> [<a href="/pmc/articles/PMC3052420/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3052420</span></a>] [<a href="/pubmed/20886637" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20886637</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.turgeon.2015.923">Turgeon CT, Orsini JJ, Sanders KA, Magera MJ, Langan TJ, Escolar ML, Duffner P, Oglesbee D, Gavrilov D, Tortorelli S, Rinaldo P, Raymond K, Matern D. Measurement of psychosine in dried blood spots - a possible improvement to newborn screening programs for Krabbe disease. <span><span class="ref-journal">J Inherit Metab Dis. </span>2015;<span class="ref-vol">38</span>:923–9.</span> [<a href="/pubmed/25762404" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25762404</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.ungari.2015.15038">Ungari S, Montepeloso A, Morena F, Cocchiarella F, Recchia A, Martino S, Gentner B, Naldini L, Biffi A. Design of a regulated lentiviral vector for hematopoietic stem cell gene therapy of globoid cell leukodystrophy. <span><span class="ref-journal">Mol Ther Methods Clin Dev. </span>2015;<span class="ref-vol">2</span>:15038.</span> [<a href="/pmc/articles/PMC4605225/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4605225</span></a>] [<a href="/pubmed/26509184" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26509184</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.wasserstein.2016.1235">Wasserstein MP, Andriola M, Arnold G, Aron A, Duffner P, Erbe RW, Escolar ML, Estrella L, Galvin-Parton P, Iglesias A, Kay DM, Kronn DF, Kurtzberg J, Kwon JM, Langan TJ, Levy PA, Naidich TP, Orsini JJ, Pellegrino JE, Provenzale JM, Wenger DA, Caggana M. Clinical outcomes of children with abnormal newborn screening results for Krabbe disease in New York State. <span><span class="ref-journal">Genet Med. </span>2016;2016;<span class="ref-vol">18</span>:1235–43.</span> [<a href="/pubmed/27171547" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27171547</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.wenger.2013">Wenger D, Escolar ML, Luzi P, Rafi MA. Krabbe disease (globoid cell leukodystrophy). In: Valle D, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, ed. <em>The Online Metabolic and Molecular Bases of Inherited Diseases.</em> New York: McGraw-Hill. 2013.</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.wenger.2003">Wenger DA. Krabbe disease: globoid cell leukodystrophy. In: Rosenberg RN, Prusiner SB, DiMauro S, Barchi RL, Nestler EJ, eds. <em>The Molecular and Genetic Basis of Neurologic and Psychiatric Disease.</em> Philadelphia: Butterworth-Heinemann; 2003:255-61.</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.wenger.2014.307">Wenger DA, Luzi P, Rafi MA. Krabbe disease: are certain mutations disease-causing only when specific polymorphisms are present or when inherited in trans with specific second mutations? <span><span class="ref-journal">Mol Genet Metab. </span>2014;<span class="ref-vol">111</span>:307–8.</span> [<a href="/pubmed/24388568" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24388568</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.wenger.1997.268">Wenger DA, Rafi MA, Luzi P. Molecular genetics of Krabbe disease (globoid cell leukodystrophy): diagnostic and clinical implications. <span><span class="ref-journal">Hum Mutat. </span>1997;<span class="ref-vol">10</span>:268–79.</span> [<a href="/pubmed/9338580" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9338580</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.wenger.2001">Wenger DA, Suzuki K, Suzuki Y, Suzuki K. Galactosylceramide lipidosis. Globoid cell leukodystrophy (Krabbe disease). In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Vogelstein B, eds. <em>The Metabolic and Molecular Bases of Inherited Disease.</em> 8 ed. McGraw-Hill; 2001:3669-94.</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.wright.2017.1365">Wright MD, Poe MD, DeRenzo A, Haldal S, Escolar ML. Developmental outcomes of cord blood transplantation for Krabbe disease: A 15-year study. <span><span class="ref-journal">Neurology. </span>2017;<span class="ref-vol">89</span>:1365–72.</span> [<a href="/pmc/articles/PMC5649761/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5649761</span></a>] [<a href="/pubmed/28855403" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28855403</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.zhang.2018.174">Zhang T, Yan C, Ji K, Lin P, Chi L, Zhao X, Zhao Y. Adult-onset Krabbe disease in two generations of a Chinese family. <span><span class="ref-journal">Ann Transl Med. </span>2018;<span class="ref-vol">6</span>:174.</span> [<a href="/pmc/articles/PMC5994525/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5994525</span></a>] [<a href="/pubmed/29951496" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29951496</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="krabbe.REF.zuccoli.2015.739">Zuccoli G, Narayanan S, Panigrahy A, Poe MD, Escolar ML. Midbrain morphology reflects extent of brain damage in Krabbe disease. <span><span class="ref-journal">Neuroradiology. </span>2015;<span class="ref-vol">57</span>:739–45.</span> [<a href="/pubmed/25859833" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25859833</span></a>]</div></li></ul></div><div id="krabbe.Author_Notes"><h3>Author Notes</h3><p>The Program for Neurodevelopment in Rare Disorders Registry<br />4401 Penn Ave, Plaza building 4th Floor<br />Pittsburgh, PA 15224<br /><b>Phone:</b> 412-692-6350<br /><b>Website:</b>
<a href="http://www.chp.edu/research/areas/neurodevelopment" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.chp.edu/research/areas/neurodevelopment</a></p></div><div id="krabbe.Author_History"><h3>Author History</h3><p>Michele Caggana, ScD (2018-present)<br />Stephanie Coppola, BS; Thomas Jefferson University, Pennsylvania (2004-2006)<br />Maria L Escolar, MD (2018-present)<br />Joseph J Orsini, PhD (2018-present)<br />Melissa P Wasserstein, MD (2018-present)<br />David A Wenger, PhD; Thomas Jefferson University, Pennsylvania (2000-2018)</p></div><div id="krabbe.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>11 October 2018 (bp) Comprehensive update posted live</div></li><li class="half_rhythm"><div>31 March 2011 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>5 August 2008 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> available clinically for <i>GALC</i></div></li><li class="half_rhythm"><div>3 January 2007 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>27 September 2004 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>25 November 2002 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>19 June 2000 (me) Review posted live</div></li><li class="half_rhythm"><div>February 2000 (dw) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1238</span><span class="label">PMID: <a href="/pubmed/20301416" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301416</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/mdel17q21_31/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/l1cam/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1238&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1238/?report=reader">PubReader</a></li><li><a href="/books/NBK1238/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1238" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1238" style="display:none" title="Cite this Page"><div class="bk_tt">Orsini JJ, Escolar ML, Wasserstein MP, et al. Krabbe Disease. 2000 Jun 19 [Updated 2018 Oct 11]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1238/pdf/Bookshelf_NBK1238.pdf">PDF version of this page</a> (490K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#krabbe.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#krabbe.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#krabbe.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#krabbe.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#krabbe.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#krabbe.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#krabbe.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#krabbe.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#krabbe.References" ref="log$=inpage&amp;link_id=inpage">References</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2581[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">GALC</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1489806" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1489806" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1489806" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1489806" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28579020" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Psychosine, a marker of Krabbe phenotype and treatment effect.</a><span class="source">[Mol Genet Metab. 2017]</span><div class="brieflinkpop offscreen_noflow">Psychosine, a marker of Krabbe phenotype and treatment effect.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Escolar ML, Kiely BT, Shawgo E, Hong X, Gelb MH, Orsini JJ, Matern D, Poe MD. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Mol Genet Metab. 2017 Jul; 121(3):271-278. Epub 2017 May 22.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301309" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Arylsulfatase A Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Arylsulfatase A Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Gomez-Ospina N. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24006547" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ornithine Transcarbamylase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ornithine Transcarbamylase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lichter-Konecki U, Caldovic L, Morizono H, Simpson K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31536184" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Glutaric Acidemia Type 1</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Glutaric Acidemia Type 1<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Larson A, Goodman S. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301601" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Neuronal Ceroid-Lipofuscinoses</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Neuronal Ceroid-Lipofuscinoses<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Mole SE, Williams RE. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301416" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301416" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e0428e739a66ee2ba95ab85">Krabbe Disease - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Krabbe Disease - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T22:28:39-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal101&amp;ncbi_phid=CE88599FE041D54100000000054B01FB&amp;ncbi_session=CE88599FE0428E71_1355SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1238%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1238&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1238/&amp;ncbi_pagename=Krabbe Disease - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE88599FE0428E71_1355SID /projects/books/PBooks@5.22 portal101 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>